# The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Study · id `cardio:ct-nct05374291` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05374291](<https://clinicaltrials.gov/study/NCT05374291>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05374291

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Heart failure; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1750 participants.

## Technical summary

Registry record NCT05374291. Randomized; double masking; primary purpose prevention. Start 2022-11-08 (actual); primary completion 2027-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1750 participants (planned count; ClinicalTrials.gov record NCT05374291, source copy `cardio:ctgov-nct05374291-2026-10-08`, retrieved 2026-10-26)
- Started: 2022-11-08 (actual) (ClinicalTrials.gov record NCT05374291, source copy `cardio:ctgov-nct05374291-2026-10-08`, retrieved 2026-10-26)
- Primary completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT05374291, source copy `cardio:ctgov-nct05374291-2026-10-08`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT05374291, source copy `cardio:ctgov-nct05374291-2026-10-08`, retrieved 2026-10-26)
- Countries: Australia; Belgium; Germany; Netherlands; Singapore; Spain (ClinicalTrials.gov record NCT05374291, source copy `cardio:ctgov-nct05374291-2026-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05374291-2026-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
- Condition: Kidney Disease, Chronic
- Condition: Renal Transplant Failure
- Condition: Heart Failure
- Condition: Kidney Failure
- Condition: Death
- Intervention (Drug): Dapagliflozin 10 mg/day (oral)
- Intervention (Drug): Placebo
- Lead sponsor: University Medical Center Groningen
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Dutch Kidney Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 46775ac8d7bbb8a64c18ec74e9855d6184e1ef26570512edb79a09114d476f0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
